Department of Chemistry and Biochemistry and the Harper Cancer Research Institute, University of Notre Dame , Notre Dame, Indiana 46656, United States.
Epigenetics Program, Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania 19104, United States.
Anal Chem. 2017 Mar 7;89(5):2773-2781. doi: 10.1021/acs.analchem.6b03602. Epub 2017 Feb 21.
Multicellular tumor spheroids (MCTS) are valuable in vitro tumor models frequently used to evaluate the penetration and efficacy of therapeutics. In this study, we evaluated potential differences in epigenetic markers, i.e., histone post-translational modifications (PTMs), in the layers of the HCT116 colon carcinoma MCTS. Cells were grown in agarose-coated 96 well plates, forming reproducible 1-mm-diameter MCTS. The MCTS were fractionated into three radially concentric portions, generating samples containing cells from the core, the mid and the external layers. Using mass spectrometry (MS)-based proteomics and EpiProfile, we quantified hundreds of histone peptides in different modified forms; by combining the results of all experiments, we quantified the abundance of 258 differently modified peptides, finding significant differences in their relative abundance across layers. Among these differences, we detected higher amounts of the repressive mark H3K27me3 in the external layers, compared to the core. We then evaluated the epigenetic response of MCTS following UNC1999 treatment, a drug targeting the enzymes that catalyze H3K27me3, namely, the polycomb repressive complex 2 (PRC2) subunits enhancer of zeste 1 (EZH1) and enhancer of zeste 2 (EZH2). UNC1999 treatment resulted in significant differences in MCTS diameter under drug treatment of varying duration. Using matrix-assisted laser desorption/ionization (MALDI) imaging, we determined that the drug penetrates the entire MCTS. Proteomic analysis revealed a decrease in abundance of H3K27me3, compared to the untreated sample, as expected. Interestingly, we observed a comparable growth curve for MCTS under constant drug treatment over 13 days with those treated for only 4 days at the beginning of their growth. We thus demonstrate that MS-based proteomics can define significant differences in histone PTM patterns in submillimetric layers of three-dimensional (3D) cultures. Moreover, we show that our model is suitable for monitoring drug localization and regulation of histone PTMs after drug treatment.
多细胞肿瘤球体(MCTS)是一种常用的体外肿瘤模型,可用于评估治疗药物的穿透性和疗效。在这项研究中,我们评估了 HCT116 结肠癌细胞 MCTS 层中表观遗传标记(即组蛋白翻译后修饰(PTMs))的潜在差异。细胞在琼脂糖涂层的 96 孔板中生长,形成可重复的 1mm 直径的 MCTS。MCTS 被分成三个径向同心部分,产生包含核心、中层和外层细胞的样本。使用基于质谱(MS)的蛋白质组学和 EpiProfile,我们定量了数百种不同修饰形式的组蛋白肽;通过结合所有实验的结果,我们定量了 258 种不同修饰肽的丰度,发现它们在层间的相对丰度存在显著差异。在这些差异中,我们检测到与核心相比,外部层中抑制性标记 H3K27me3 的含量更高。然后,我们评估了 MCTS 在 UNC1999 治疗后的表观遗传反应,UNC1999 是一种针对催化 H3K27me3 的酶(即多梳抑制复合物 2(PRC2)亚基增强子结合锌指蛋白 1(EZH1)和增强子结合锌指蛋白 2(EZH2)的药物。UNC1999 处理在不同持续时间的药物处理下导致 MCTS 直径的显著差异。使用基质辅助激光解吸/电离(MALDI)成像,我们确定药物穿透整个 MCTS。蛋白质组学分析显示,与未处理的样品相比,H3K27me3 的丰度降低,这是预期的结果。有趣的是,我们观察到在 13 天的持续药物处理下,MCTS 的生长曲线与仅在生长初期处理 4 天的 MCTS 相似。因此,我们证明了基于 MS 的蛋白质组学可以定义三维(3D)培养物亚毫米层中组蛋白 PTM 模式的显著差异。此外,我们表明我们的模型适用于监测药物定位和药物处理后组蛋白 PTM 的调节。